Quit


Return



My Profile






Mobile mode
logo
RenAdaptor web Server
© copyright 2009 Using this information remains the sole and exclusive responsibility of the user
Last update : 2018-09-14

General references

1The Principles and Practice of Nephrology by Jacobson, Striker & Klahr : Chapter 146 Dosing regimens in renal disease. Brater DC. Tables 146-2 to 146-5. B.C. Decker Inc., 1991.
2Textbook of nephrology third edition by Massry & Glassock : Section 9: Management of the uremic state: Table 84.11. Lippincott Williams & Wilkins, 1995.
3

Clinical Dialysis third edition by Nissenson, Fine & Gentile : Clinical dialysis - Drug usage in dialysis patients: Tables 34-11 to 34-14. International Edition, 1995.

4Replacement of renal function by dialysis fourth revised edition by Jacobs, Kjellstrand, Koch & Winchester : Drug dosage in dialysis patients . 29 . Golper TA, Marx MA, Shuler C, Bennett WM. Tables 11 to 20. Kluwer Academic Publishers, 1996.
5The Kidney fifth edidtion by Brenner & Rector : Management of the patient with renal failure . 60 . Shuler C, Golper TA and Bennett WM . Prescribing drugs in renal disease. W.B. Saunders, 1996.
6

Poison Index, the treatment of acute intoxication by Seyffart G. 4. Edition. PABST Science Publishers 1997.

7Poisoning & Toxicology Compendium by Leikin JB,  Paloucek FP. APhA - Lexi-comp 1998.
8

Update on psychotropic medication use in renal disease. Cohen LM, Tessier EG, Germain MJ, Levy NB. Psychosomatics. 2004 Jan-Feb;45(1):34-48.

9

Guides de prescription des médicaments chez le patient insuffisant rénal - ICAR : GPR antihypertenseurs 1ere édition (2002), GPR Insuffisance cardiaque 1ere édition (2004), GPR antibactériens 2è édition (2005), GPR antiviraux 3è édition (2007), GPR anticancéreux 3è édition (2005) - Méditions International.

10Drug prescribing in renal failure fifth edition by Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, Pasko DA, Smoyer WE. American college of Physicians Philadelphia, 2007.
11

The Renal Drug Reference Guide (First Edition), Cervelli MJ (B.Pharm). MJC Pharma, Adelaide, 2007.

12

Drug dosing adjustments in patients with chronic kidney disease. Munar MY, Singh H. Am Fam Physician. 2007 May 15;75(10):1487-96.

13

Therapeutic Drug Monitoring Data. A Concise Guide. Third Edition. Hammett-Stabler CA, Dasgupta A. AACCPress, Washington 2007.

14

Drug removal by plasmapheresis: an evidence-based review by Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, Edwards DJ. Pharmacotherapy 2007; 27(11): 1529-49.

15

Compendium AGIM 1998 – 2008.

16Dialysis of drugs by Johnson CA. Amgen Canada Inc. 2008.
17

Use of hemodialysis and hemoperfusion in poisoned patients. Holubek WJ, Hoffman RS, Goldfarb DS, Nelson LS. Kidney Int. 2008 Nov;74(10):1327-34.

18Altered nonrenal drug clearance in ESRD. Nolin TD. Curr Opin Nephrol Hypertens. 2008 Nov;17(6):555-9.
19

Martindale thirty-sixth edition - The complete drug reference edited by  Sweetman SC. The pharmaceutical press, 2009.

20Compendium Medex-Medasso, 2009.
21

The Renal Drug Handbook (Third Edition), Ashley C, Currie A, UK Renal Pharmacy Group. Radcliffe Publishing Oxford, New York, 2009.

22Psychotropic drugs and renal failure: translating the evidence for clinical practice. Baghdady NT, Banik S, Swartz SA, McIntyre RS. Adv Ther. 2009 Apr;26(4):404-24.
23

Use of antibacterial agents in renal failure by Gilbert B, Robbins P, Livornese LL. Infect Dis Clin N Am Dec. 2009; 23: 899-924.

24

Comprehensive Clinical Nephrology (Fourth Edition). Floege J, Johnson RJ, Feehally J : Principles of Drug Therapy, Dosing and Prescribing in Chronic Kidney Disease and Renal Replacement Therapy. Cervelli MJ, Russ GR; Pages 871-893. Elsevier Saunders, St Louis, 2010.

25

Dialysis in the poisoned patient. Bayliss G. Hemodial Int. 2010 Apr;14(2):158-67.

26

Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. N Engl J Med. 2010 Apr 29;362(17):1575-85.

27Continuous renal replacement therapy does not have a clear role in the treatment of poisoning. Kim Z, Goldfarb DS. Nephron Clin Pract. 2010;115(1):1-6.
28

Drug renal toxicity. Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C. Nephrol & Therap. 2010; 6(1): 58-74.

29Seyffart's Directory of Drug Dosage in Kidney Disease. Seyffart G. Dustri-Verlag Dr. Karl Feistle. Munich 2011.
30

Pharmacotherapy - A Pathophysiologic Approach, 8th Edidtion by JT.Dipiro & all. Chapter 48: Drug Theray Individualization in Patients with Hepatic Disease. Lam YWF;  pages 705-710. Chapter 57: Drug Therapy Individualisation for Patients with Chronic Kidney Disease. Matzke GR; pages 861-872. Mc Graw Hill Medical, New York, 2011.

31Drugs and the liver. Edited by Penny North-Lewis. Pharmaceutical Press, London, 2011.
32Prescribing medications in patients with decompensated liver cirrhosis. Amarapurkar DN. Int J Hepatol. 2011;2011:519526.
33

Opioid and benzodiazepine use in end-stage renal disease: a systematic review. Wyne A, Rai R, Cuerden M, Clark WF, Suri RS. Clin J Am Soc Nephrol. 2011 Feb;6(2):326-33.

34

Use of antibacterial agents in renal failure by B.Gilbert, P.Robbins, L.L.Livornese. ÝMed Clin North Am. 2011 Jul; 95(4):677-702.

35

Therapeutics in Kidney Disease. Challenges, Innovations, Opportunities. Arya V, Pfister M, Nolin TD. J Clin Pharmacol. 2012 Jan;52(Suppl 1):1S-140S.

36

Agents anti-infectieux et fonction rénale: vers des posologies sur mesure ? [Antimicroblal agents and renal elimination: towards individual dosage adjustment?]. Willi-Robatel C, Senn L, Livio F, Zanetti G, Marchetti O, Buclin T. Rev Med Suisse. 2012 Apr 25;8(338):894-900.

37Répertoire commenté des médicaments C.B.I.P. 1998 – 2013.
38The Sanford Guide to antimicrobial therapy 1998 – 2013.
39

KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int Suppl. 2013 jan;(3):S91-111.

40

Medications and therapeutic apheresis procedures: are we doing our best? Ibrahim RB, Balogun RA. J Clin Apher. 2013 Feb;28(1):73-7.

41

KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int suppl. 2013;3:1-150.

42

Review article: prescribing medications in patients with cirrhosis - a practical guide. Lewis JH, Stine JG. Aliment Pharmacol Ther. 2013 Jun;37(12):1132-56.

43

Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. Franz CC, Hildbrand C, Born C, Egger S, Rätz Bravo AE, Krähenbühl S. Eur J Clin Pharmacol. 2013 Aug;69(8):1565-73.

44

Renal Pharmacotherapy. Dosage Adjustment of Medications Eliminated by the Kidneys. Golightly LK, Teitelbaum I, Kiser TH, Levin DA, Barber GR, Jones MA, Stolpman NM, Lundin KS. Springer Science+Business Media New York 2013.

45

Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease. Weir MR, Fink JC. Curr Opin Nephrol Hypertens. 2014 May;23(3):306-13.

46

Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Velenosi TJ, Urquhart BL. Expert Opin Drug Metab Toxicol. 2014 Aug;10(8):1131-43.

47

Prescription of potentially inappropriate medications to elderly hemodialysis patients: prevalence and predictors. Kondo N, Nakamura F, Yamazaki S, Yamamoto Y, Akizawa T, Akiba T, Saito A, Kurokawa K, Fukuhara S. Nephrol Dial Transplant. 2015 Mar;30(3):498-505.

48

Chronic liver injury induced by drugs: a systematic review. Stine JG, Chalasani N. Liver Int. 2015 Nov;35(11):2343-53.

49

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. N Engl J Med. 2015 Nov 26;373(22):2103-16.

50

Adherence with renal dosing recommendations in outpatients undergoing haemodialysis. Kim GJ, Je NK, Kim DS, Lee S. J Clin Pharm Ther. 2016 Feb;41(1):26-33.

51

Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged =75 Years: A Randomized Clinical Trial. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM; SPRINT Research Group. JAMA. 2016 Jun 28;315(24):2673-82.

52

Renal Drug Dosing. Effectiveness of Outpatient Pharmacist-Based vs. Prescriber-Based Clinical Decision Support Systems. Vogel EA, Billups SJ, Herner SJ, Delate T. Appl Clin Inform. 2016 Jul 27;7(3):731-44.

53

Effect of Intensive Blood Pressure Control on Gait Speed and Mobility Limitation in Adults 75 Years or Older: A Randomized Clinical Trial. Odden MC, Peralta CA, Berlowitz DR, Johnson KC, Whittle J, Kitzman DW, Beddhu S, Nord JW, Papademetriou V, Williamson JD, Pajewski NM; Systolic Blood Pressure Intervention Trial (SPRINT) Research Group. JAMA Intern Med. 2017 Apr 1;177(4):500-507.

54

BP Reduction, Kidney Function Decline, and Cardiovascular Events in Patients without CKD. Magriço R, Bigotte Vieira M, Viegas Dias C, Leitão L, Neves JS. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):73-80.

55

Néphrotoxicité médicamenteuse [Drug nephrotoxicity]. Izzedine H. Nephrol Ther. 2018 May;14(3):127-134.

56

Introduction to Nephropharmacology for the Clinician: A New CJASN Series. Nolin TD, Perazella MA. Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1083-1084.

57

Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles. Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1085-1095.]

58

Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens. Roberts DM, Sevastos J, Carland JE, Stocker SL, Lea-Henry TN. Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1254-1263.

59

Clinical Pharmacodynamics: Principles of Drug Response and Alterations in Kidney Disease. Keller F, Hann A. Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1413-1420.

60

Use of extracorporeal treatments in the management of poisonings. Ghannoum M, Hoffman RS, Gosselin S, Nolin TD, Lavergne V, Roberts DM. Kidney Int. 2018 Oct;94(4):682-688.

61

Clinical Pharmacogenomics: Applications in Nephrology. Adams SM, Crisamore KR, Empey PE. Clin J Am Soc Nephrol. 2018 May 23. [Epub ahead of print]

62

Medication Safety Principles and Practice in CKD. Whittaker CF, Miklich MA, Patel RS, Fink JC. Clin J Am Soc Nephrol. 2018 Jun 18. [Epub ahead of print]

References specific to each molecule may also appear on the information page of all cards

Internet References
    

www.uptodate.com
www.ncbi.nlm.nih.gov
www.fda.gov
www.emea.europa.eu
www.drugs.com
www.rxlist.com
www.cbip.be
www.pharma.be
www.vidalpro.net
www.docguide.com
www.cme.medscape.com/nephrology
www.soc-nephrologie.org/
www.sitegpr.com
www.doseadapt.unibas.ch
www.dosing.de
www.cebam.be
www.fagg-afmps.be
www.whocc.no/atc_ddd_index/
www.inchem.org
www.wikipedia.org
www.google.be
www.unboundmedicine.com/ucentral/index/Johns_Hopkins_ABX_Guide/All_Topics/A


banner